The pet food industry is one of the most environmentally costly sectors in the global food system. Cats and dogs in the United States alone consume enough animal-derived calories to rival the dietary footprint of a country the size of France. The meat and fish used in conventional pet food production contributes to deforestation, water stress, greenhouse gas emissions, and the ethical concerns that have begun to reshape how consumers think about their own diets. For a growing number of pet owners who have already reduced their personal meat consumption for environmental or animal welfare reasons, the disconnect between their own food choices and what they feed their pets has become an uncomfortable one.
Lab-grown pet food, produced through cellular agriculture using cultured animal cells rather than slaughtered animals, has emerged as one proposed solution to this problem. The basic premise is straightforward: take a small number of cells from a living animal, culture them in a bioreactor with the nutrients they need to multiply, and produce meat without the animal agriculture supply chain that conventional pet food depends on. If the technology works at scale and the price comes down far enough, the environmental and ethical case is compelling.
But the question this essay examines is not whether lab-grown pet food is theoretically possible. It demonstrably is, and in early 2025 it became commercially real for the first time. The question is whether it can genuinely replace traditional meat-based diets for dogs and cats within a decade, and whether the barriers standing between current early-stage products and mass-market adoption are surmountable in that timeframe.
The Case For: Why Lab-Grown Pet Food Has Real Momentum
The regulatory milestone that matters most happened in February 2025, when London-based startup Meatly launched the world’s first commercially available cultivated meat pet food product. Working in partnership with plant-based dog food brand THE PACK, Meatly’s Chick Bites combined cultivated chicken with plant-based ingredients and went on sale at Pets at Home in Brentford, London. This followed the UK Food Standards Agency’s 2024 approval of cell-cultivated chicken as a legitimate pet food ingredient, making the UK the first European country to commercially approve lab-grown meat in any food category.
The regulatory achievement matters because it demonstrates that the pathway from laboratory to retail shelf is navigable. Czech startup Bene Meat Technologies had earlier received an EU permit for cultivated meat in pet food, and Singapore has an active pipeline of cultivated ingredient approvals. The commercial ecosystem developing around lab-grown pet food is more substantial than most consumers realise. BioCraft Pet Nutrition has developed cultured chicken cell lines specifically optimised for pet food applications, producing a meat slurry format comparable to the animal-derived slurries already used in mainstream wet pet food manufacturing. In July 2024, Meatly secured a strategic investment and distribution partnership with Pets at Home specifically to scale commercial production. In November 2024, Cult Food Science acquired a majority stake in Singapore-based Umami Bioworks, which had developed cultivated red snapper fish as a cat food ingredient, to accelerate commercialisation.
The global lab-grown pet food market was valued at approximately $75 million in 2024 and is projected to reach $481 million by 2033, growing at a compound annual rate of 19.5%. Dog food currently represents the largest segment, but cat food is the fastest-growing application. Europe, driven by UK and Czech regulatory leadership, is expected to sustain the highest regional growth rate through the forecast period.
For pet owners, there is also a quality and safety argument beyond environmental concerns. Conventional pet food supply chains have experienced significant disruption since the COVID-19 pandemic. Cultivated meat produced in controlled bioreactor environments is free of antibiotics, certain pathogens, and the supply chain contamination risks associated with conventional rendered meat ingredients. Several veterinary nutritionists have noted that controlled production environments could yield more consistent nutritional profiles than conventional rendered meat, where quality varies with the source animal and processing conditions.
The Case Against: Why a Decade Is an Optimistic Timeline
The honest counterargument begins with scale. The Meatly Chick Bites launch in February 2025 was a limited release at a single Pets at Home store in Brentford, London. It was a proof-of-concept commercial milestone, not the beginning of a mass-market transition. The gap between a limited-edition product at one location and a product that genuinely replaces conventional meat-based pet food for the 180 million dogs and cats in the United States, or the 35 million pets in the UK, is not a gap that closes within a decade without overcoming cost barriers that have so far proved stubborn across the entire cultured meat sector.
The cost problem in cellular agriculture is structural, not incidental. Producing cultured meat requires growth media, bioreactor infrastructure, sterile processing facilities, and significant energy inputs. For human-consumption cultured meat, production costs have fallen dramatically since the first lab-grown burger cost over $300,000 to produce in 2013, but commercially viable, price-competitive production has not been achieved at scale. Pet food operates on even tighter margins than human food. Conventional dry dog food typically costs between $1 and $4 per kilogram at retail. Cultivated meat ingredients produced at current scale cannot approach that price point, which is why the first commercial lab-grown pet food products are positioned as premium treats rather than nutritional staple foods.
The regulatory landscape outside the UK and Singapore remains complex. In the United States, the FDA approved cultivated chicken from UPSIDE Foods and GOOD Meat for human consumption in 2023, but has not yet cleared cultivated meat as a pet food ingredient. The US pet food market is the largest in the world, and without FDA approval, the pathway to replacing conventional diets in the US market remains blocked. The political environment for novel food technologies in the US has become more complex since 2024, and regulatory timelines for novel ingredient approvals are not predictable.
There is also the question of what cats specifically require. Cats are obligate carnivores with strict biological requirements for taurine, arachidonic acid, vitamin A from retinol, and other nutrients that must come from animal sources. While cultivated meat can in principle provide these nutrients, the nutritional completeness of cultivated-meat-based cat food has not been validated through long-term feeding studies with the rigour that regulatory bodies require for established pet foods. Dogs are omnivores with more nutritional flexibility, but cats present a harder formulation challenge that the industry has not yet fully resolved at commercial scale.
What the Evidence Shows About the Timeline
The evidence supports genuine technological progress combined with commercial and regulatory challenges that make full replacement of traditional meat-based pet diets within a decade unlikely for most markets.
The production format for pet food may offer an easier route to cost parity than human-consumption cultured meat. Pet food does not require the whole-muscle meat textures that make producing appealing human food products so technically complex. The meat slurry format that BioCraft and others are developing is structurally simpler to produce, requires less complex scaffolding, and can be mixed with plant-based ingredients in proportions that reduce the cultured meat content required per serving. This means the cost trajectory for cultivated pet food ingredients may reach viability sooner than equivalent human food products, though the timeline remains uncertain.
The UK market is the most credible near-term test case. With regulatory approval in place, a major retail distribution partner committed, and growing consumer interest in sustainable pet care, the conditions for accelerated commercial development exist. If the sector can expand from limited-release premium treats to national distribution of complete nutritional products within the next two to three years, the UK could demonstrate meaningful market penetration within the decade. That would be significant, but still one market rather than global replacement.
Research from Professor Andrew Knight at the University of Winchester has provided supporting evidence that nutritionally complete alternative protein pet foods, including both cultivated and plant-based formulations, can deliver equivalent or better health outcomes for dogs and cats compared to conventional meat-based diets. That research removes one significant objection to the transition and provides a scientific foundation for nutritional claims that the industry will need when marketing to health-conscious pet owners.
The Verdict: Possible in a Decade, Probable in Two
Lab-grown pet food replacing traditional meat-based diets within a decade is possible in specific market conditions and improbable as a global outcome. The technology is real and advancing. The regulatory pathway is open in at least two major jurisdictions. The commercial ecosystem is building with credible participants and genuine investment. The pet food format advantages over human cultured meat products are real and may compress the cost timeline meaningfully.
But the decade framing assumes a pace of cost reduction, regulatory expansion, consumer adoption, and production scale-up that has not been demonstrated in any cultivated food category to date. The more likely trajectory is that lab-grown pet food establishes a meaningful premium market position within a decade in the UK and select other markets, achieves price parity with mid-market conventional pet food in the fifteen to twenty year timeframe as production technology matures, and becomes genuinely mainstream only once the full global regulatory picture is resolved.
For pet owners who want to reduce the environmental footprint of their pet’s diet now, the most immediately practical options remain high-quality plant-based pet foods, already commercially available and nutritionally validated for dogs, and the emerging hybrid cultivated-and-plant-based products in markets where they are available. The full replacement of traditional meat-based pet diets is a direction of travel the industry is moving toward with genuine momentum. Whether it arrives within a decade depends on whether cost and regulatory barriers fall faster than they have in any comparable food technology transition so far. The broader question of whether cellular agriculture can make traditional livestock farming economically obsolete by 2050 places the pet food question in its full context: pet food may actually prove the easier and faster transition, given the production format advantages, while the wider transformation of the human food system faces a longer and harder road. The regulatory and scientific relationship between veterinary and human biotechnology applications is also at the heart of the debate over whether veterinary gene therapy should be regulated as strictly as human gene therapy, where companion animals serve as both patients and research subjects in ways that shape the safety standards applied to both domains. A comparable pattern of genuine but bounded disruption appears in the question of whether mycelium-based biomaterials can realistically replace single-use plastics in global packaging, where the technology works well in specific applications without displacing the broader market.
Leave a Reply